|
Background: :Nonalcoholic fatty liver disease (NAFLD) is a pathological change of liver tissue which resembles to that of alcoholic fat ty liver disease , but it is a clinicopathological syndrome without alcohol consumption.In the past decades, there has been a rapid increase in the prevalence of morbid obesity, type 2 diabetes, hypertension, hyperlipidemia with the improvement of living standard. Meanwhile we find that nonalcoholic fatty liver disease (NAFLD) is a common chronic liver condition worldwide,and its morbidity is rising year by year. Estimated to occur in 30% of adults in the United States,the paediatric population is not far behind ,with up to 10% affected. It can occur at any age and at any race,even happens at children aged 2 years to 3 years. The spectrum of the disease ranges from simple steatosis, a reversible condition, to inflammation and fibrosis (nonalcoholic steatohepatitis or NASH), a progressive disease. A total of 10% to 22% percent of those with NASH will ultimately develop cirrhosis and hepatocellular carcinoma,and liver fibrosis is the only way which cirrhosis must pass.If we can reverse liver fibrosis in NASH,cirrhosis and hepatocellulat carcinoma will not occur. But there are no specific and efficient interventions. Therefore,many investigators focus on the intervention study of reversing liver fibrosis from NASH.Objective: Diammonium glycyrrihizinate can proctect liver cell,resist inflammation and oxidation. Fuzheng huayu capsule can inhibit HSC activation, reduce the production of collagen,accelerate the collagen resolving and etc. And rosiglitazone can improve IR of patient with NAFLD. This reseach aimed to investigate the indexes of liver fibrosis nd insulin resistance in NAFLD by combining these drugs.Methods: 91 cases with NAFLD were divided into three groups : group A( n = 31) , group B( n = 29) and group C( n=31 ) . Serum levels of FBG, FNS, HA, P - III - P,LN and IVC were measured at the start and end of the experiment in all cases. And compute HOMA-IR. All groups are the same low fat diet. The group A was treated with fuzheng huayu capsule, diammonium glycyrrihizinate and rosiglitazone for six months. Group B was given with fuzheng huayu capsule and diammonium glycyrrihizinate for six months. The group C was only given with diammonium glycyrrihizinate for six months.We monitor the blood routine, urine routine, liver function, renal function, blood lipid,FNS and FBG at the start ,the 1st month,the 3rd month and the end of the experiment.The indexes of insulin resistance and liver fibosis were compared.Results:(1)HOMA - I R, HA, P - III - P,LN and IVC were all decreased significantly in patients of the group A compared with before treatment( P < 0.05). (2) In the group B the liver fibrosis indexes were all decreased compared with before treatment ( P < 0.05) ,but HOMA-IR had no statistical change ( P >0.05) . (3) Index of insulin resistance had no significant change compared with before treatment in the group C( P >0.05),while HA, P - III - P,LN and IVC had statistical change ( P < 0.05).(4) there were much decreased in group A that in group B and C( P < 0.05).Conclusion: fuzheng huayu capsule and diammonium glycyrrihizinate combined with rosiglitazone have better protection from liver fibrosis in NAFLD than fuzheng huayu capsule and diammonium glycyrrihizinate.
|